Osteoporosis - Intermittent Dosing and Multiple Indications Drive Market Growth

Introduction

Osteoporosis therapy has been largely focused on antiresorptive drugs that reduce the rate of bone loss. The condition is the focus of attention of significant R&D activity, with drugs in development both in existing classes offering advantages over marketed products and novel drugs exploiting genomics programs and a deeper understanding of bone biology. 

Scope

Epidemiology of osteoporosis in the seven major markets by disease severity, identification of niche populations and unmet needs 

Detailed profiles of drugs in Phase II and above. Analysis examines clinical data, patient potential, marketing factors, satisfaction of unmet needs 

Primary research with key osteoporosis opinion leaders providing insight on future market entrants and innovative R&D projects in the disease area 

Pharma Market Forecast model shows market potential with global sales forecasts for key pipeline drugs, currently marketed products and classes 

Report Highlights

Novel bisphosphonates, Zometa and Boniva, with their novel dosing regimens and delivery methods, will lead growth in the osteoporosis market, as R&D osteoporosis drugs will reach sales of $4.7 billion by 2011. 

Driven by new market leader Evista, which will lead Pfizer’s lasofoxifene and Wyeth’s bazedoxifene by targeting multiple indications, the SERMs drug class will be valued at $4.2 billion by 2011. 

The osteoporosis early stage pipeline consists largely of drug candidates in new therapeutic classes, in particular cathepsin K inhibitors, osteoprotegerin and calcilytics. While these drugs have the potential to change the face of osteoporosis treatment in the long term, innovative approaches will likely be costly to patients, limiting potential. 

Reasons to Purchase

Validate internal forecasts against drug/class sales model and assess market potential for pipeline products 

Analyze competitive environment at time of product launch to inform best strategy for market entry 

Highlight key R&D trends and company involvement in the market to inform licensing decisions and identify potential partners based on R&D activity. 

January 2004, 264 pages 

Publisher: Datamonitor Womens Health Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Womens_Health.html#a565